15783-48-9

Usage

Uses

Used in Pharmaceutical Industry:
2,4-dihydroxyfuro[3,4-d]pyrimidin-7(5H)-one is used as a potential anticancer agent for its ability to form DNA cross-links, leading to cytotoxicity in cancer cells. Its role in inhibiting the enzyme dihydrouracil dehydrogenase also makes it a promising candidate for enhancing the efficacy of the anticancer drug 5-fluorouracil.
Used in Biochemical Research:
2,4-dihydroxyfuro[3,4-d]pyrimidin-7(5H)-one is used as a research compound for studying its biological activity and potential applications in the development of new pharmaceuticals and bioactive molecules. Its unique structure and properties make it an interesting subject for further investigation in the field of biochemistry and molecular biology.

Upstream product

• 4156-75-6 furo<3,4-d>pyrimidine-2,4,7(1H,3H,5H)-trione 
• 4156-75-6 2,4-dihydroxyfuro[3,4-d]pyrimidin-7(5H)-one 

Downstream Products

• 15783-56-9 2-chloro-4-(phenylamino)furo[3,4-d]pyrimidin-7(5H)-one 
• 15783-58-1 2-chloro-4-(4-hydroxy-anilino)-5H-furo[3,4-d]pyrimidin-7-one 
• 1079651-75-4 4-(benzhydryl-amino)-2-chloro-5H-furo[3,4-d]pyrimidin-7-one 
• 1262443-70-8 4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-chlorofuro[3,4-d]pyrimidin-7(5H)-one 
• 1079651-81-2 4-(benzhydryl-amino)-2-morpholin-4-yl-5H-furo[3,4-d]pyrimidin-7-one 
• 1365640-48-7 C₂₃H₂₃N₅O₂ 
• 1365640-49-8 C₂₅H₂₅N₅O₃ 
• 1365640-50-1 C₂₂H₂₂N₄O₃ 
• 1365640-51-2 C₂₄H₂₅N₅O₂ 
• 1079651-82-3 2-(4-acetyl-piperazin-1-yl)-4-(benzhydryl-amino)-5H-furo[3,4-d]pyrimidin-7-one 
• 1079654-86-6 4-(benzhydryl-amino)-6-isopropyl-2-morpholin-4-yl-5,6-dihydro-pyrrolo[3,4-d]pyrimidin-7-one 
• 1365640-52-3 C₂₄H₂₅N₅O₄S 
• 1365640-53-4 C₂₇H₃₀N₆O₃ 
• 1365640-54-5 C₂₇H₃₀N₆O₃ 

Relevant academic research and scientific papers

Probing the Reactivity of 2,4-Dichlorofuro[3,4-d ]pyrimidin-7-one: A Versatile and Underexploited Scaffold to Generate Substituted or Fused Pyrimidine Derivatives

Herein, we describe the results of our investigation on the chemical reactivity and versatility of a poorly explored scaffold: 2,4-dichlorofuro[3,4-d ]pyrimidin-7-one (3). Highly functionalized pyrimidines can be obtained with a divergent approach by reacting the key intermediate 3 with different amine nucleophiles under carefully controlled reaction conditions. The set-up of a microwave-Assisted one-pot, two-or three-step protocol to rapidly generate 2,4,5,6-Tetrasubstituted or fused pyrimidines is also reported.

Discovery of P2X3 selective antagonists for the treatment of chronic pain

Purinergic receptor P2X3 has been linked to analgesia in a number of pre-clinical models of pain, and is expressed in the human pain perception pathway. Only few P2X3-selective antagonists have been reported to date. This Letter describes the SAR and in vivo analgesic profile of a novel scaffold of selective P2X3 antagonists.

DIHYDROFUROPYRIMID1NE COMPOUNDS

The present invention provides mTOR inhibitors of the formula (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods of making the compounds and intermediates thereof; and methods of using the compounds.

DIHYROFUROPYRMINDINE COMPOUNDS

The present invention provides mTOR inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods of making the compounds and intermediates thereof; and methods of using the compounds.

OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).